Trade Names:Entereg- Capsules, oral 12 mg
Antagonizes the peripheral effects of opioids on GI motility and secretion by competitively binding to GI tract mu-opioid receptors.
Following oral administration, C max is approximately 2 h postdose. Absolute bioavailability is approximately 6%.
Vd is approximately 30 L. Plasma protein binding (to albumin) of alvimopan and its metabolite averages 80% and 94%, respectively.
No evidence of hepatic metabolism. Unabsorbed and unchanged drug is hydrolyzed to the metabolite by gut microflora.
Renal excretion accounts for approximately 35% of the total drug Cl. The metabolite is eliminated in the feces and urine. Mean terminal t ½ of alvimopan and the metabolite range from 10 to 17 h and 10 to 18 h, respectively.
The t ½ was comparable in patients with mild or moderate renal function impairment. There may be drug accumulation in patients with severe renal function impairment receiving multiple doses.Hepatic Function Impairment
Drug exposure tended to be higher in patients with mild or moderate hepatic function impairment compared with healthy controls. There were no consistent effects on C max or t ½ in patients with hepatic function impairment.Elderly
No dosage adjustment is needed.Gender
Gender does not affect the pharmacokinetics of alvimopan.Race
Dosage adjustments are not necessary based on race.
Accelerate the time of upper and lower GI recovery following partial large or small bowel resection surgery with primary anastomosis.
Patients who have taken opioids for more than 7 consecutive days prior to taking alvimopan.
PO 12 mg 30 min to 5 h prior to surgery followed by 12 mg twice daily beginning the day after surgery for a max of 7 days or until discharge (max, 15 doses).
Store at 59° to 86°F.
None well documented.
None well documented.
Constipation (10%); flatulence (9%); dyspepsia (7%).
Urinary retention (4%).
Back pain (3%).
Available only for short-term use in hospitalized patients.
Closely monitor patients with mild to moderate hepatic or mild to severe renal function impairment for adverse reactions.
Category B .
Safety and efficacy not established.
Not recommended in patients with end-stage renal disease.
Not recommended for use in patients with severe hepatic function impairment. There is a potential for 10-fold higher plasma levels in patients with severe hepatic function impairment.
Not recommended for use in patients undergoing surgery for correction of complete bowel obstruction.
Patients recently exposed to opioids are expected to be more sensitive to alvimopan GI adverse reactions.
Conflicting results; however, a 12-month study of patients receiving opioids for chronic pain found an increase in MI in patients receiving alvimopan 0.5 mg twice daily compared with placebo.
Data not available; single doses of up to 120 mg and multiple doses of up to 48 mg for 7 days were well tolerated by healthy subjects.
Copyright © 2009 Wolters Kluwer Health.